Rintodestrant

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameRintodestrant
Drug Alias Nameoral SERDG1T-48G1T48
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEstrogen receptors degraders
TargetsEstrogen receptors
Therapy Area/IndicationsMetastatic breast cancerBreast NeoplasmsCarcinoma, Ductal, Breast
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaUnited States +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesG1 Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesG1 Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerBreast NeoplasmsCarcinoma, Ductal, Breast
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A